A class of weight loss drugs best known for transforming waistlines may also save knees. New research suggests that medications like semaglutide could prevent tens of thousands of knee replacement surgeries each year in the United Kingdom alone.
The study, led by researchers at the University of Oxford, looked at what happens when people with obesity and knee osteoarthritis take GLP-1 receptor agonists. These drugs, originally developed for diabetes, trigger significant weight loss. And weight loss, the data shows, directly reduces the mechanical stress on damaged knee joints.
How the study worked and what it found
The Oxford team analyzed health records from the UK and modeled the potential impact of widespread use of these drugs among patients who qualify for knee replacement. They estimated that if all eligible patients took the medication, roughly 28,000 knee replacements could be avoided each year. That is about a quarter of all such surgeries performed annually in the country.
Knee replacement is a major operation. It requires weeks of recovery and carries risks including infection, blood clots, and implant failure. For many patients, the procedure is the only option after years of pain from osteoarthritis, a condition where cartilage wears away and bone rubs against bone. Obesity is a major driver of that wear.
Why this matters to patients and the health system
For the people who would avoid surgery, the benefit is straightforward: no hospital stay, no rehabilitation, no surgical scars. But the ripple effects are large. The UK performs more than 100,000 knee replacements each year, and the National Health Service spends hundreds of millions of pounds on them. Reducing that number by a quarter would free up operating rooms, surgeons, and beds for other patients.
Local doctors and patient advocates have long said that weight loss is the most effective way to manage knee osteoarthritis. But sustained weight loss is difficult. Many patients struggle to lose enough weight through diet and exercise alone to make a difference. The new drugs change that calculus. They produce an average weight loss of 15 percent of body weight, enough in many cases to ease joint pain and delay or eliminate the need for surgery.
The study did not look at the cost of the drugs versus the cost of surgery. It also did not track long term outcomes for patients who took the medication instead of having an operation. But the numbers are large enough that health officials are paying attention.
What happens next
The Oxford researchers say their findings should prompt a broader conversation about how to treat knee osteoarthritis. For decades, the medical establishment has offered patients a choice between painkillers, physical therapy, and eventually surgery. Weight loss drugs now present a fourth option, one that addresses the root cause of the joint damage rather than just the symptoms.
The study was published in the British Journal of Sports Medicine. It adds to a growing body of evidence that GLP-1 drugs have effects far beyond weight loss, including reducing heart attacks, strokes, and now, perhaps, the need for joint replacement. For the millions of people with aching knees, the news offers a path that does not end in an operating room.
